Preliminary assessment of cardiotoxicity in chimeric antigen receptor T cell therapy: a systematic review and meta-analysis

Guo, Minjia; Wang, Xiaotong; Xiao, Shengjue; Liu, Aili; Xu, Tao; Huan, Chunyan; Wu, Huimin; Hu, Yue; Zhou, Shuaishuai; Zhu, Hong; Pan, Defeng

doi:10.1007/s10238-023-01042-z

Cited by 4 publications

(2 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incidence of cardiac events in patients receiving CAR-T cells varies between studies but is generally between 10 and 20% and occurs mainly in CRS grade ≥2 with elevated cardiac troponin and interleukin-6. 67 68 69 70 71 72 73 The most frequently observed CV events are profound hypotension requiring vasopressor support, arrhythmias including AF and ventricular tachycardias, as well as left ventricular dysfunction, decompensated HF, and CV death. 67 68 69 70 71 72 73…”

Section: Cardiotoxicity Of Targeted Therapies In Hematologymentioning

confidence: 99%

See 1 more Smart Citation

Cardio-Oncology: A New Discipline in Medicine and Its Relevance to Hematology

Spannbauer,

Bergler-Klein

2024

Hamostaseologie

View full text Add to dashboard Cite

Cardio-oncology, a burgeoning subspecialty, addresses the complex interplay between cardiology and oncology, particularly in light of increased cardiovascular (CV) disease mortality in cancer patients. This review provides a comprehensive overview of cardio-oncology with a focus on the therapies used in hematological malignancies. We explore the bidirectional relationship between heart failure and cancer, emphasizing the need for collaborative care. The review discusses risk stratification, highlighting the importance of baseline CV risk assessment and personalized surveillance regimens. Primary and secondary prevention strategies, including pharmacological interventions, are outlined. The review also delves into the cardiotoxicity associated with hematological cancer therapies, focusing on anthracyclines, Bruton kinase inhibitors, BCR-ABL tyrosine kinase inhibitors, CAR-T cell therapy, immune checkpoint inhibitors, multiple myeloma treatments, and hematopoietic stem cell transplantation. We then highlight the high risk of venous and arterial thromboembolisms in cancer patients and the challenges of anticoagulation management in cardio-oncology. Finally, the review touches on the importance of long-term follow-up and appropriate screening in cancer survivors at high risk of CV morbidity and mortality, based on their CV risk profile and the type and dose of cardiotoxic therapies they received such as anthracyclines or high radiation doses.

show abstract

Section: Cardiotoxicity Of Targeted Therapies In Hematologymentioning

confidence: 99%

“…67 68 69 70 71 72 73 The most frequently observed CV events are profound hypotension requiring vasopressor support, arrhythmias including AF and ventricular tachycardias, as well as left ventricular dysfunction, decompensated HF, and CV death. 67 68 69 70 71 72 73…”

Section: Cardiotoxicity Of Targeted Therapies In Hematologymentioning

confidence: 99%